Giuseppe Rosano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11850085/publications.pdf

Version: 2024-02-01

100	10,871	71004	43601
papers	citations	43	95
		h-index	g-index

100	100	100	15094
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 187-210.	1.4	10
2	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	0.8	11
3	Sodiumâ€“glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	2.9	67
4	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 132-142.	2.9	30
5	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	2.9	41
6	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). European Heart Journal, 2022, 43, 2185-2195.	1.0	12
7	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
8	Headâ€toâ€head comparison between recommendations by the <scp>ESC</scp> and <scp>ACC</scp>/<scp>AHA</scp>/<scp>HFSA</scp> heart failure guidelines. European Journal of Heart Failure, 2022, 24, 916-926.	2.9	18
9	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170.	2.9	13
10	Prevention of sudden death in heart failure with reduced ejection fraction: do we still needÂan implantable cardioverterâ€defibrillator for primary prevention?. European Journal of Heart Failure, 2022, 24, 1460-1466.	2.9	12
11	The New ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: the Good and the Not So Good. Current Problems in Cardiology, 2021, 46, 100554.	1.1	10
12	Selfâ€care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 157-174.	2.9	181
13	Expect the Unexpected in the Medical Treatment of Heart Failure with Reduced Ejection Fraction: between Scientific Evidence and Clinical Wisdom. International Journal of Heart Failure, 2021, 3, 205.	0.9	4
14	Management of Heart Failure Patient with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1131-1139.	2.2	36
15	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	2.9	37
16	Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 539-546.	1.4	22
17	Pharmacotherapy adherence in patients with heart failure: Easier said than done. International Journal of Cardiology, 2021, 332, 135-137.	0.8	2
18	Cardiac, renal, and metabolic effects of sodiumâ€“glucose coâ€transporter 2 inhibitors: a position paper from the European Society of Cardiology adâ€hoc task force on sodiumâ€“glucose coâ€transporter 2 inhibitors. European Journal of Heart Failure, 2021, 23, 1260-1275.	2.9	36

#	Article	IF	Citations
19	â€˜Time is prognosisâ€™ in heart failure: timeâ€toâ€treatment initiation as a modifiable risk factor. ESC Heart Failure, 2021, 8, 4444-4453.	1.4	37
20	Association between betaâ€blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity scoreâ€matched analysis from the Swedish Heart Failure Registry. European Journal of Heart Failure, 2020, 22, 103-112.	2.9	27
21	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	2.9	47
22	Epidemiology, pathophysiology and contemporary management of cardiogenic shockÂâ€“Âa position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	2.9	244
23	2019 guidelines for the diagnosis and management of chronic coronary syndromes: congratulations and criticism. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 331-332.	1.4	3
24	Management and outcomes of heart failure patients with CKD: experience from an interâ€disciplinary clinic. ESC Heart Failure, 2020, 7, 3225-3230.	1.4	14
25	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
26	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	2.9	35
27	Acute heart failure congestion and perfusion statusÂâ€“Âimpact of the clinical classification on inâ€hospital and longâ€term outcomes; insights from the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2019, 21, 1338-1352.	2.9	170
28	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction ChangeÂin HeartÂFailure. JACC: Heart Failure, 2019, 7, 306-317.	1.9	125
29	Renal function, electrolytes, and congestion monitoring in heart failure. European Heart Journal Supplements, 2019, 21, M25-M31.	0.0	11
30	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	1.2	39
31	Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment. American Journal of Cardiology, 2019, 123, 233-238.	0.7	15
32	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
33	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2018, 39, 2274-2281.	1.0	16
34	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.	1.0	426
35	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€“European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	1.0	171
36	Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-15.	1.9	237

#	Article	IF	Citations
37	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 230-236.	1.4	39
38	Foreword. Cardiac Failure Review, 2018, 4, 68.	1.2	0
39	Foreword. Cardiac Failure Review, 2018, 4, 68-69.	1.2	0
40	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. European Heart Journal, 2017, 38, ehw149.	1.0	511
41	Comprehensive efforts to increase adherence to statin therapy. European Heart Journal, 2017, 38, ehw628.	1.0	40
42	Essential role of ICAM-1 in aldosterone-induced atherosclerosis. International Journal of Cardiology, 2017, 232, 233-242.	0.8	104
43	Heart Rate and Rhythm and the BenefitÂofÂBeta-Blockers in PatientsÂWithÂHeart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896.	1.2	198
44	Observational Versus Randomized. JACC: Heart Failure, 2017, 5, 395-396.	1.9	0
45	The mitochondrial metabolic reprogramming agent trimetazidine as an â€˜exercise mimeticâ€™ in cachectic C26â€bearing mice. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 954-973.	2.9	63
46	Comparison of Low-Dose Statin Versus Low-Dose Statinâ€‰+â€‰Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial). American Journal of Cardiology, 2017, 120, 893-897.	0.7	28
47	Human cells involved in atherosclerosis have a sex. International Journal of Cardiology, 2017, 228, 983-1001.	0.8	25
48	Modulating the metabolism by trimetazidine enhances myoblast differentiation and promotes myogenesis in cachectic tumor-bearing c26 mice. Oncotarget, 2017, 8, 113938-113956.	0.8	29
49	Are elderly and women under-represented in cardiovascular clinical trials? Implication for treatment. Wiener Klinische Wochenschrift, 2016, 128, 433-438.	1.0	14
50	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	2.9	455
51	Improvement of skeletal muscle performance in ageing by the metabolic modulator Trimetazidine. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 449-457.	2.9	44
52	Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
53	Effect of age and sex on efficacy and tolerability of Î² blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855.	3.0	95
54	Animal models of cardiac cachexia. International Journal of Cardiology, 2016, 219, 105-110.	0.8	27

#	Article	IF	Citations
55	Bisoprolol pharmacokinetics and body composition in patients with chronic heart failure: a longitudinal study. European Journal of Clinical Pharmacology, 2016, 72, 813-822.	0.8	17
56	Foreword. Cardiac Failure Review, 2016, 2, 6.	1.2	0
57	Transparency in medical research: Time for a paradigm shift. Clinical Trials and Regulatory Science in Cardiology, 2015, 2-3, 1-3.	1.0	0
58	Comorbidities Frequency in Takotsubo Syndrome: An International Collaborative Systematic Review Including 1109 Patients. American Journal of Medicine, 2015, 128, 654.e11-654.e19.	0.6	157
59	The Reply. American Journal of Medicine, 2015, 128, e11.	0.6	13
60	Apaf1-deficient cortical neurons exhibit defects in axonal outgrowth. Cellular and Molecular Life Sciences, 2015, 72, 4173-4191.	2.4	7
61	Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy. Journal of Thrombosis and Thrombolysis, 2015, 40, 331-339.	1.0	4
62	Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease. American Journal of Cardiology, 2015, 116, 1798-1801.	0.7	40
63	Need for gender-specific pre-analytical testing: The dark side of the moon in laboratory testing. International Journal of Cardiology, 2015, 179, 514-535.	0.8	23
64	Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in highâ€fatâ€dietâ€fed mice. FASEB Journal, 2014, 28, 3745-3757.	0.2	139
65	Mineralocorticoid receptor in adipocytes and macrophages: A promising target to fight metabolic syndrome. Steroids, 2014, 91, 46-53.	0.8	58
66	Takotsubo Syndrome (Stress Cardiomyopathy): An Intriguing Clinical Condition in Search of Its Identity. American Journal of Medicine, 2014, 127, 699-704.	0.6	66
67	Effect of High-Intensity interval training versus moderate continuous training on 24-h blood pressure profile and insulin resistance in patients with chronic heart failure. Internal and Emergency Medicine, 2014, 9, 547-552.	1.0	51
68	The heart and the gut. European Heart Journal, 2014, 35, 426-430.	1.0	123
69	The challenge of performing effective medical research in the era of healthcare data protection. International Journal of Cardiology, 2014, 177, 510-511.	0.8	8
70	Validation of rate of perceived exertion-based exercise training in patients with heart failure: Insights from autonomic nervous system adaptations. International Journal of Cardiology, 2014, 176, 394-398.	0.8	21
71	Efficacy of Î² blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet, The, 2014, 384, 2235-2243.	6.3	475
72	Exercise-Induced Skeletal Muscle Remodeling and Metabolic Adaptation: Redox Signaling and Role of Autophagy. Antioxidants and Redox Signaling, 2014, 21, 154-176.	2.5	157

#	Article	IF	Citations
73	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. International Journal of Cardiology, 2014, 172, 403-410.	0.8	36
74	Matched dose interval and continuous exercise training induce similar cardiorespiratory and metabolic adaptations in patients with heart failure. International Journal of Cardiology, 2013, 167, 2561-2565.	0.8	101
75	Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. International Journal of Cardiology, 2013, 169, 262-270.	0.8	27
76	Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. International Journal of Cardiology, 2013, 163, 320-325.	0.8	77
77	A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. Journal of the American College of Cardiology, 2013, 61, 131-142.	1.2	154
78	Doseâ€“response relationship of baroreflex sensitivity and heart rate variability to individually-tailored exercise training in patients with heart failure. International Journal of Cardiology, 2013, 166, 334-339.	0.8	42
79	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094.	2.9	182
80	The metabolic modulator trimetazidine triggers autophagy and counteracts stressâ€induced atrophy in skeletal muscle myotubes. FEBS Journal, 2013, 280, 5094-5108.	2.2	39
81	A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention. American Heart Journal, 2012, 163, 1019-1023.	1.2	41
82	Exogenous Testosterone, Cardiovascular Events, and Cardiovascular Risk Factors in Elderly Men: A Review of Trial Data. Journal of Sexual Medicine, 2012, 9, 54-67.	0.3	59
83	Oral contraceptives modify DNA methylation and monocyte-derived macrophage function. Biology of Sex Differences, 2012, 3, 4.	1.8	50
84	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
85	Tai Chi Enhances the Effects of Endurance Training in the Rehabilitation of Elderly Patients with Chronic Heart Failure. Rehabilitation Research and Practice, 2011, 2011, 1-6.	0.5	41
86	A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. Therapeutic Delivery, 2011, 2, 1437-1453.	1.2	28
87	Gender Disparity in Susceptibility to Oxidative Stress and Apoptosis Induced by Autoantibodies Specific to RLIP76 in Vascular Cells. Antioxidants and Redox Signaling, 2011, 15, 2825-2836.	2.5	56
88	Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Advances in Therapy, 2011, 28, 1105-1113.	1.3	103
89	Aldosterone Regulates Vascular Gene Transcription via Oxidative Stressâ€“Dependent and â€“Independent Pathways. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1871-1880.	1.1	78
90	Testosterone Deficiency and Exercise Intolerance in Heart Failure: Treatment Implications. Current Heart Failure Reports, 2010, 7, 59-65.	1.3	24

#	Article	IF	Citations
91	Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome: Results from a 24-month, Randomized, Double-Blind, Placebo-Controlled Study. Journal of Sexual Medicine, 2010, 7, 3495-3503.	0.3	208
92	Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. International Journal of Cardiology, 2010, 142, 50-55.	0.8	61
93	Cell sex determines anoikis resistance in vascular smooth muscle cells. FEBS Letters, 2009, 583, 3448-3454.	1.3	50
94	Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Advances in Therapy, 2009, 26, 455-461.	1.3	31
95	Functional Mineralocorticoid Receptors in Human Vascular Endothelial Cells Regulate Intercellular Adhesion Molecule-1 Expression and Promote Leukocyte Adhesion. Circulation Research, 2008, 102, 1359-1367.	2.0	237
96	Research Resource: Rapid Recruitment of Temporally Distinct Vascular Gene Sets by Estrogen. Molecular Endocrinology, 2008, 22, 2544-2556.	3.7	25
97	Cardiac Metabolism in Myocardial Ischemia. Current Pharmaceutical Design, 2008, 14, 2551-2562.	0.9	97
98	The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction. Current Pharmaceutical Design, 2008, 14, 3749-3757.	0.9	19
99	Editorial [Hot Topic:Metabolic Therapy: An Important Therapeutic Option for the Treatment of Cardiovascular Diseases (Executive Editors: G.M.C. Rosano and G. Barbaro)]. Current Pharmaceutical Design, 2008, 14, 2519-2520.	0.9	4
100	Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment. Endocrine-Related Cancer, 2007, 14, 61-72.	1.6	17